Table 5.
Integrated CANVAS 1 and 2: clinical cure rates by infection type at the test-of-cure visit
| Type of infection | Cure rate (%)
|
||
|---|---|---|---|
| Ceftaroline | Vancomycin plus aztreonam | Difference, (%) (95% CI) | |
| Microbiologically evaluable | 434/468 (92.7) | 421/446 (94.4) | −1.7 (−4.9 to 1.6) |
| Gram positive only | 348/371 (93.8) | 330/350 (94.3) | −0.5 (−4.1 to 3.1) |
| Gram negative only | 9/34 (85.3) | 24/24 (100) | −15.6 (−31.6 to −1.2) |
| Mixed gram positive and negative | 57/63 (90.5) | 67/72 (93.1) | −2.6 (−13.4 to 7.2) |
| Polymicrobial infection | 125/136 (91.9) | 134/139 (96.4) | −4.2 (−10.5 to 1.5) |
Note: Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51(6):641–650, by permission of Oxford University Press.66
Abbreviation: CANVAS, ceftaroline versus v ancomycin in skin and skin structure infections; CI, confidence interval.